Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Stock
Fundamentals
Source: third-party data provider, as of October 9, 2026
Compare with AUPH
Recent news

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
AUPH

AUPH Stock Rallies 6% After-Hours — Here’s Why
AUPH Stock Rallies 6% After-Hours — Here’s Why
AUPH

Aurinia Settles Patent Litigation with Teva
Aurinia Settles Patent Litigation with Teva
AUPH

Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates
Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates
AUPH
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 50.58
- MACD 12/26/9
- -0.07
- EMA 9 of MACD
- 0.00
- MACD histogram
- -0.07
- SMA 50
- $16.05
- Price above SMA 50
- EMA 50
- $16.13
- Price above EMA 50
- SMA 200
- $15.56
- Price above SMA 200
- EMA 200
- $15.49
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 1 analyst
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
AUPH

AUPH Stock Rallies 6% After-Hours — Here’s Why
AUPH Stock Rallies 6% After-Hours — Here’s Why
AUPH

Aurinia Settles Patent Litigation with Teva
Aurinia Settles Patent Litigation with Teva
AUPH

Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates
Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates
AUPH

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
AUPH

Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
AUPH

Aurinia (AUPH) Upgraded to Strong Buy: Here's Why
Aurinia (AUPH) Upgraded to Strong Buy: Here's Why
AUPH

Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
AUPH

5 Small Drug Stocks to Invest in Amid a Biotech Comeback
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
AUPH

Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last?
Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last?
AUPH
News tone: automated (AI) classification of the article's content, not a price prediction.
About Aurinia Pharmaceuticals Inc Ordinary Shares
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Kevin C. Tang | Chairman & CEO | 1967 |
| Mr. Stephen P. Robertson | Chief Legal Officer, Corporate Secretary & Chief Compliance Officer | 1982 |
| Mr. Peter S. Greenleaf M.B.A. | Consultant | 1970 |
| Mr. Michael S. Hearne CPA | Chief Financial Officer | 1963 |
| Mr. Ryan Cole | Chief Operating Officer | 1987 |
| Mr. Thomas Wei | Chief Scientific Officer | 1976 |
| Mr. Stewart M. Kroll | Chief Development Officer | 1959 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 9, 2026
Technical indicators
- RSI 14
- 50.58
- MACD 12/26/9
- -0.07
- EMA 9 of MACD
- 0.00
- MACD histogram
- -0.07
- SMA 50
- $16.05
- Price above SMA 50
- EMA 50
- $16.13
- Price above EMA 50
- SMA 200
- $15.56
- Price above SMA 200
- EMA 200
- $15.49
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $16.00
- Average
- $16.00
- High
- $16.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +61.5 | -42.3 | +28.6 | |||||||||
| 2022 | -25.9 | -30.3 | +3.1 | -18.3 | +3.6 | -9.3 | -28.2 | -9.6 | +3.2 | +9.9 | -36.0 | -14.8 |
| 2023 | +52.4 | -1.9 | +21.9 | +9.0 | -20.0 | +6.1 | +15.9 | -13.2 | -17.9 | -1.3 | +21.2 | -0.8 |
| 2024 | -13.7 | -26.0 | -13.3 | -5.7 | +4.2 | +6.5 | +7.1 | +21.4 | +9.7 | -0.7 | +21.0 | -1.3 |
| 2025 | -9.4 | +1.8 | +0.8 | +2.4 | -4.4 | +6.4 | +23.7 | +14.3 | -5.4 | +15.5 | +22.4 | -1.4 |
| 2026 | -5.3 | -6.9 | +4.3 | -0.5 | -0.1 | +10.8 | -5.8 | +10.6 | +0.9 | +1.7 |



